Pancreatic Cancer Research

ResearcherUniversity of OxfordActive in the last 2 years

Shihong Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-7952-7965; OpenAlex author ID A5103851145. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2019: 5 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Coordinated immune architecture underlies durable survival in pancreatic cancer Co-author DOI 10.64898/2026.04.29.721612↗
  2. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Co-author DOI 10.1038/s41467-024-55424-2↗
  3. METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-dependent manner. Co-author DOI 10.1016/j.canlet.2023.216222↗
  4. Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreati… Co-author DOI 10.1186/s13578-023-01155-8↗
  5. Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2 Pathway. Co-author DOI 10.1016/j.jcmgh.2022.07.008↗
  6. Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway. Co-author DOI 10.1016/j.omto.2020.03.006↗
  7. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biocel.2019.01.011↗
  8. ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. First author DOI 10.1016/j.omto.2019.07.005↗
  9. Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis. Co-author DOI 10.1186/s12876-019-0975-3↗
  10. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. Co-author DOI 10.1186/s13046-019-1209-9↗
  11. Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cel… Co-author DOI 10.1186/s13578-019-0312-0↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 7 shared papers, 2019–2023 · strength 0.86
  2. Tao Yin · 6 shared papers, 2019–2023 · strength 0.82
  3. Hehe Li · 5 shared papers, 2019–2023 · strength 0.63
  4. Qingke Duan · 4 shared papers, 2019–2023 · strength 0.48
  5. Chunyou Wang · 4 shared papers, 2019–2023 · strength 0.48
  6. Zhengle Zhang · 3 shared papers, 2019–2023 · strength 0.38
  7. Rachael J. M. Bashford-Rogers · 2 shared papers, 2025–2026 · strength 0.37
  8. Michael Loran Dustin · 2 shared papers, 2025–2026 · strength 0.37
  9. Adam Enver Frampton · 2 shared papers, 2025–2026 · strength 0.37
  10. Shivan Sivakumar · 2 shared papers, 2025–2026 · strength 0.37
  11. Zibo Meng · 3 shared papers, 2019–2022 · strength 0.36
  12. Jiaoshun Chen · 2 shared papers, 2022–2023 · strength 0.34
  13. Haoxiang Zhang · 2 shared papers, 2022–2023 · strength 0.34
  14. Zhiqiang Liu · 3 shared papers, 2019–2020 · strength 0.33
  15. Jingyuan Zhao · 2 shared papers, 2019–2020 · strength 0.22
  16. Anguraj Sadanandam · 1 shared paper, 2026 · strength 0.21
  17. Nabeel Merali · 1 shared paper, 2026 · strength 0.21
  18. Nicola E. Annels · 1 shared paper, 2026 · strength 0.21
  19. Tarak Agrebi Moumni Chouari · 1 shared paper, 2026 · strength 0.21
  20. Elisa Giovannetti · 1 shared paper, 2026 · strength 0.21
  21. Alex Nicolas Gordon-Weeks · 1 shared paper, 2026 · strength 0.21
  22. Hengqiang Zhao · 2 shared papers, 2019 · strength 0.20
  23. Samarth Hegde · 1 shared paper, 2025 · strength 0.16
  24. Miriam Merad · 1 shared paper, 2025 · strength 0.16
  25. Lara Rosaline Heij · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.